James Crowe Jr.

December 3, 2015

Caucus explores crucial role of NIH research funding

James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, and Anthony Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), recently participated in a U.S. Senate National Institutes of Health (NIH) caucus briefing held in Washington, D.C., by Senate NIH caucus co-chairs Sens. Lindsey Graham (R-SC) and Dick Durbin (D-IL).

By John Howser
blood draw
October 19, 2015

Two Ebola Survivors’ Blood Could Help Vanderbilt Researchers Find A Treatment

By VUMC News and Communications
September 24, 2015

Survivors of Ebola outbreak take part in VUMC vaccine study

Two survivors of a 2014 Ebola outbreak in Nigeria visited Vanderbilt University Medical Center last week to share their experiences and participate in a study aimed at finding ways to treat the often-fatal infection.

By Bill Snyder
Ebola virus under microscope.
September 10, 2015

Ebola symposium to feature Nigerian physicians

Three Nigerian physicians who survived Ebola virus disease in July 2014 after coming in direct contact with an Ebola-infected patient will speak at Vanderbilt University Medical Center next Wednesday, Sept. 16.

By Bill Snyder
July 24, 2015

How to trick a wily virus

Vanderbilt investigators have discovered how human antibodies induced during testing of an experimental “bird flu” vaccine kill the virus.

By Sanjay Mishra
July 9, 2015

Study could lead to vaccine for mosquito-borne dengue virus

Researchers at Vanderbilt University and the National University of Singapore have determined the structure of a human monoclonal antibody which, in an animal model, strongly neutralizes a type of the potentially lethal dengue virus.

By Bill Snyder
July 8, 2015

Vanderbilt researchers develop potential treatment to fight mosquito-borne chikungunya virus

In late 2013 the Caribbean had its first case of the mosquito-borne chikungunya virus. Today there have been almost 1.2 million cases in 44 countries or territories, including 177 cases in 31 U.S. States.
By Nancy Humphrey
May 21, 2015

‘Redesigned’ antibodies may control HIV: study

With the help of a computer program called “Rosetta,” researchers at Vanderbilt University have “redesigned” an antibody that has increased potency and can neutralize more strains of the AIDS-causing human immunodeficiency virus (HIV) than can any known natural antibody.
By Bill Snyder
May 15, 2015

VU lands $9 million NIH grant to design better flu vaccines

Vanderbilt University researchers have received a five-year, $9 million grant from the National Institutes of Health (NIH) to design more effective flu vaccines and novel antibody therapies.
By Bill Snyder
April 8, 2015

VU joins national effort to speed Ebola therapy testing

Vanderbilt University researchers have joined a multi-center effort led by Pennsylvania-based Inovio Pharmaceuticals Inc. to accelerate development of potential antibody therapies against the often-lethal Ebola virus.
By Bill Snyder
February 26, 2015

Studies show human antibodies can fight lethal Marburg virus

Researchers at Vanderbilt University, the University of Texas Medical Branch at Galveston and The Scripps Research Institute for the first time have shown how human antibodies can neutralize the Marburg virus, a close cousin to Ebola.
By Bill Snyder
January 29, 2015

Core facilities key driver of VUMC research gains

During the past five years, Vanderbilt University Medical Center has become a leader in “personalized medicine,” the use of genomic information to individualize patient care.
By Bill Snyder
October 28, 2014

Vanderbilt researchers isolate Ebola-fighting human antibodies for possible treatment

Vanderbilt University researchers have isolated Ebola-fighting human antibodies – the first of their kind – that could lead to a new treatment for the deadly virus.
By VUMC News and Communications
1 … 5 6 7 8 9